Overview

Drug Treatment for Pathologic Gambling Disorder

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Naltrexone